Tobacco use is the number one preventable cause of death in the US. The reinforcing efficacy of nicotine (NIC), the most abundant alkaloid in tobacco, plays a major role in the maintenance of tobacco smoking. Furthermore, tobacco use and depressive disorders are highly comorbid, and NIC maybe be used in part to alleviate depression in this clinical population. Research on the neurobiology of reward and drug addiction has focused on mesocorticolimbic and nigrostriatal dopamine (DA) pathways. NIC activates nicotinic receptors which increases extracellular DA concentrations at both terminal and cell body regions of these pathways. Extracellular DA concentration is the net result of neurotransmitter release from the presynaptic terminal and neurotransmitter clearance from the extracellular space. DA clearance is mediated primarily by the plasma membrane dopamine transporter (DAT). Although there is a wealth of information on NIC stimulated DA release, the ability of NIC to modulate DAT function and the underlying mechanisms responsible for this effect have not been studied in detail. Preliminary data show that in prefrontal cortex, acute NIC increases DA uptake into synaptosomes, DA clearance in in vivo voltammetry studies and DAT trafficking to the cell surface. Thus, NIC augmentation of DAT function appears to sharpen the kinetics of the NIC-induced increase in extracelluar DA concentration in prefrontal cortex. The proposed study will begin to elucidate the underlying mechansims responsible for the NIC-induced enhancement of DAT function. The hypothesis to be tested in the current application is that NIC, via nicotinic receptor activation, mediates the trafficking of DAT. This hypothesis will be tested using the rat as the animal model, and will determine (1) the dose-related effects of acute in vivo administration of NIC on DAT trafficking in striatum, nucleus accumbens, prefrontal cortex and amygdala; (2) if nicotinic receptors mediate the effect of NIC on DAT trafficking; and (3) the effect of intermittent and continuous NIC administration on DAT trafficking. Results of these experiments will begin to elucidate the cellular mechanisms by which NIC and nicotinic receptors modulate DAT function, and thereby, contribute to the regulation of extracellular DA concentration. Thus, insight will be provided with respect to the effect of NIC on DA neurotransmission in brain regions associated with drug abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21DA018372-01A1
Application #
6989377
Study Section
Neurobiology of Motivated Behavior Study Section (NMB)
Program Officer
Pilotte, Nancy S
Project Start
2005-09-30
Project End
2007-08-31
Budget Start
2005-09-30
Budget End
2006-08-31
Support Year
1
Fiscal Year
2005
Total Cost
$216,256
Indirect Cost
Name
University of Kentucky
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Zhu, Jun; Bardo, Michael T; Dwoskin, Linda P (2013) Distinct effects of enriched environment on dopamine clearance in nucleus accumbens shell and core following systemic nicotine administration. Synapse 67:57-67
Zhu, Jun; Apparsundaram, Subbu; Dwoskin, Linda P (2009) Nicotinic receptor activation increases [3H]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex. J Pharmacol Exp Ther 328:931-9
Zhu, J; Reith, M E A (2008) Role of the dopamine transporter in the action of psychostimulants, nicotine, and other drugs of abuse. CNS Neurol Disord Drug Targets 7:393-409
Norrholm, Seth D; Horton, David B; Dwoskin, Linda P (2007) The promiscuity of the dopamine transporter: implications for the kinetic analysis of [3H]serotonin uptake in rat hippocampal and striatal synaptosomes. Neuropharmacology 53:982-9
Middleton, Lisa S; Apparsundaram, Subbu; King-Pospisil, Kelley A et al. (2007) Nicotine increases dopamine transporter function in rat striatum through a trafficking-independent mechanism. Eur J Pharmacol 554:128-36
Dwoskin, Linda P; Rauhut, Anthony S; King-Pospisil, Kelley A et al. (2006) Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12:178-207